Do RANKL inhibitors (denosumab) affect inflammation and immunity?
about
A High-grade Sarcoma Arising in a Patient With Recurrent Benign Giant Cell Tumor of the Proximal Tibia While Receiving Treatment With DenosumabUpdate on Inflammatory Biomarkers and Treatments in Ischemic StrokeRecognizing and treating secondary osteoporosisLong-term treatment of osteoporosis: safety and efficacy appraisal of denosumabBiologic therapies and bone loss in rheumatoid arthritis.OPG/RANKL/RANK axis is a critical inflammatory signaling system in ischemic brain in miceAdverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis.Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis.Antibody-mediated "universal" osteoclast targeting platform using calcitonin as a model drug.Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medicationsTNF Induction of NF-κB RelB Enhances RANKL-Induced Osteoclastogenesis by Promoting Inflammatory Macrophage Differentiation but also Limits It through Suppression of NFATc1 ExpressionThe challenging interplay between rheumatoid arthritis, ageing and comorbidities.Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targetsAlopecia areata after denosumab treatment for osteoporosis.A Novel Therapeutic Peptide as a Partial Agonist of RANKL in Ischemic Stroke.MKP-1 signaling events are required for early osteoclastogenesis in lineage defined progenitor populations by disrupting RANKL-induced NFATc1 nuclear translocation.Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw.Mesenchymal stem cells in osteoarticular diseases.Denosumab and the current status of bone-modifying drugs in breast cancer.Adverse drug reactions to osteoporosis treatments.The clinical use of denosumab for the management of low bone mineral density in postmenopausal women.The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction.Osteoporosis drug therapy strategies in the setting of disease-modifying agents for autoimmune disease.Osteoporosis in chronic inflammatory disease: the role of malnutrition.Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor.How Long to Treat with Denosumab.Osteonecrosis of the Jaw-a Bone Site-Specific Effect of Bisphosphonates.Macrophages and skeletal health.Factor Xa and thrombin stimulate proinflammatory and profibrotic mediator production by retinal pigment epithelial cells: a role in vitreoretinal disorders?Long-term sequential receptor activator of NF-κB ligand (RANKL) and osteoprotegrin (OPG) expression in lipopolysaccharide-induced rat periapical lesions.Effect of Twice-Yearly Denosumab on Prevention of Bone Mineral Density Loss in De Novo Kidney Transplant Recipients: A Randomized Controlled Trial.Adenovirus-mediated osteoprotegerin ameliorates cartilage destruction by inhibiting proteoglycan loss and chondrocyte apoptosis in rats with collagen-induced arthritis.Lesional infiltration of receptor activator of nuclear factor-κB ligand⁺ cells in experimental autoimmune neuritis rats.Beyond Antibodies: B Cells and the OPG/RANK-RANKL Pathway in Health, Non-HIV Disease and HIV-Induced Bone Loss.Denosumab-induced cutaneous hypersensitivity reaction with distinct clinical and histopathologic findings.The Role of MicroRNA-143-5p in the Differentiation of Dental Pulp Stem Cells into Odontoblasts by Targeting Runx2 via the OPG/RANKL Signaling Pathway.Dendritic cells: active and passive players in therapy of human diseases.Osteogenesis imperfecta and therapeutics.Current Controversies on the Pathogenesis of Medication-Related Osteonecrosis of the Jaw.
P2860
Q27000565-5191F794-322A-464F-9997-054A9D2A51F4Q28078744-57C9DEB9-5FF1-4860-B563-54DD84F9BB40Q28270738-00A8676B-F9CB-4A84-A221-A80CA1FF3CA2Q28727655-0ABAC262-17A4-4F01-B2B1-777AAD916CAEQ30243911-B52A5326-1958-4A3A-A1C8-2D31507DFFABQ33730470-6F540CD2-460A-40B9-8B92-AE029856915BQ34189582-1F3BD955-622D-4D7E-AA89-C0D942A842C2Q34381979-30D9D14C-B2B5-46C7-9C9C-DE14444ADD6CQ34774678-8B87A8BC-5EA0-4A71-BC18-46C8A3752230Q35643989-744CA618-C7A5-49C7-9BD3-1808A7285AFFQ35740351-38EA7BD2-00B9-4150-A65A-3521F0EED307Q35750113-494731E2-8A5D-49DA-85D5-E23D1778503DQ36000249-E7E24B55-3770-4672-B772-35C04AE7BF02Q36158922-F60BFCF2-EF67-4F3C-B891-26C5378D7AEEQ37150524-41BB92AF-7304-471C-AF92-A80AC87FEE86Q37449324-E8201F19-B193-498C-AA59-2F5B812DDD4DQ37622034-A8A0AE5C-F162-4E20-8195-5FE570EAA5A5Q37945476-B1418064-F5EE-45E7-BF6C-A1748182BA47Q37945681-37562A61-BD9F-45D6-BD47-1DD8F034446BQ37965768-FB815F4C-E462-4A74-9D40-5C27DCBF5D67Q37973355-4BCC2C4D-5F6A-406E-B398-FE2182B26D36Q38006918-02104C00-D775-4537-96E2-795598A3A5C7Q38029394-7BFD69A5-DCC5-4009-96B6-A6B49F1F0E96Q38041419-85369144-737E-4396-B389-0EDD2FE6BBCBQ38051265-6DB39101-AF72-4EAA-8FE1-9B1E3A9E6FA3Q38155649-2D0B334C-C81F-4211-BFC3-BCE4A17AD49AQ38609225-9D6105AD-2636-4C61-BAD3-D154D7F4A714Q38913031-CC1256E9-82B5-4293-B6D7-8BAEBF75E261Q39129914-C7407BA6-9C61-451C-99DC-D7B78237B081Q39162846-A46C44BD-8335-4B8F-BF92-4BDC920326DBQ39724201-4D5778F6-ED39-4469-8419-03728848A2BDQ40853318-9448008C-E456-40BE-8A1B-89669AF5C7BDQ41732731-77C03E9F-BCF9-459A-97EB-6D7D6B7B5894Q46069255-3B8978CA-4FC2-436A-AFAC-FAFB3344BE71Q47194100-E0B84CF7-9188-4CEF-8526-C5163441DA67Q48117380-524F53A4-DFCB-41A6-B4E8-DC4EDC609D00Q48286134-33E71AE3-5648-4C66-884B-B67CD9169884Q48356067-B1A2D2DB-E25C-497F-BB13-123271C9AA1DQ52655586-180EE1EB-7278-4153-8A8A-AFC7642F92E1Q54500167-C9B5C7E4-1E51-4F0E-AA76-DD1523C12D88
P2860
Do RANKL inhibitors (denosumab) affect inflammation and immunity?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 June 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Do RANKL inhibitors (denosumab) affect inflammation and immunity?
@en
Do RANKL inhibitors
@nl
type
label
Do RANKL inhibitors (denosumab) affect inflammation and immunity?
@en
Do RANKL inhibitors
@nl
prefLabel
Do RANKL inhibitors (denosumab) affect inflammation and immunity?
@en
Do RANKL inhibitors
@nl
P2860
P1476
Do RANKL inhibitors (denosumab) affect inflammation and immunity?
@en
P2093
S Ferrari-Lacraz
P2860
P2888
P304
P356
10.1007/S00198-010-1326-Y
P407
P577
2010-06-23T00:00:00Z